For instance, TROP2-targeting ADC, sacituzumab govitecan (IMMU-132)—an antibody–drug conjugate targeting TROP2 (trophoblast cell-surface antigen 2) antigen and delivering the cytotoxic agent SN-38, has shown promising anticancer activity and practicable safety in patients with advanced NSCLC formerly treated with chemotherapy and immunotherapy [262]. This evidence concerns the gene TACSTD2 and non-small cell lung carcinoma.